The feasibility of polypill for cardiovascular disease prevention in Asian Population

Apichard Sukonthasarn; Yook‐Chin Chia; Ji‐Guang WangJennifer NailesPeera BuranakitjaroenHuynh Van MinhNarsingh VermaSatoshi HoshideJinho ShinYuda TuranaJam Chin TayBoon Wee TeoSaulat SiddiqueJorge SisonYu‐Qing ZhangTzung‐Dau WangChen‐Huan ChenKazuomi Kario

首页> 外文期刊>The journal of clinical hypertension. >The feasibility of polypill for cardiovascular disease prevention in Asian Population

【24h】

The feasibility of polypill for cardiovascular disease prevention in Asian Population

机译：The feasibility of polypill for cardiovascular disease prevention in Asian Population

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相关主题

摘要

Polypill is a fixed‐dose combination of medications with proven benefits for the prevention of cardiovascular disease (CVD). Its role in CVD prevention has been extensively debated since the inception of this concept in 2003. There are two major kinds of polypills in clinical studies. The first is polypill that combines multiple low‐dose medications for controlling only one CVD risk factor (such as high blood pressure or high serum cholesterol). These “single‐purpose” polypills were mostly developed from original producers and have higher cost. The polypill that combines 3‐4 pharmaceutical components, each with potential to reduce one major cardiovascular risk factors is “multi‐purpose” or “cardiovascular” polypill. Using data from various clinical trials and from meta‐analysis, Wald and Law claimed that this “cardiovascular” polypill when administered to every individual older than 55 years could reduce the incidence of CVD by more than 80. Several short and intermediate to long‐term studies with different cardiovascular polypills in phase II and III trials showed that they could provide better adherence, equivalent, or better risk factor control and quality of life among users as compared to usual care. One recently published randomized controlled clinical trial demonstrated the effectiveness and safety of a four‐component polypill for both primary and secondary CVD prevention with acceptable number needed to treat (NNT) to prevent one major cardiovascular event. Considering the slow achievement of CVD prevention in many poor‐ and middle‐income Asian countries and also the need to further improve compliance of antihypertensive and lipid lowering medications in many high‐income Asian countries, the concept of “cardiovascular polypill” could be very useful. With further support from ongoing polypill cardiovascular outcome trials, polypill could be the foundation of the population‐based strategies for CVD prevention.

著录项

来源
《The journal of clinical hypertension.》 |2021年第3期|545-555|共11页
作者
Apichard Sukonthasarn; Yook‐Chin Chia; Ji‐Guang WangJennifer NailesPeera BuranakitjaroenHuynh Van MinhNarsingh VermaSatoshi HoshideJinho ShinYuda TuranaJam Chin TayBoon Wee TeoSaulat SiddiqueJorge SisonYu‐Qing ZhangTzung‐Dau WangChen‐Huan ChenKazuomi Kario;
展开▼
作者单位

Cardiology Division Department of Internal Medicine Faculty of Medicine Chiang Mai University Chiang Mai Thailand;

Department of Medical Sciences School of Healthcare and Medical Sciences Sunway University Bandar Sunway Selangor Darul Ehsan Malaysia;

Department of Primary Care Medicine Faculty of Medicine University of Malaya Kuala Lumpur MalaysiaDepartment of Hypertension Centre for Epidemiological Studies and Clinical Trials The Shanghai Institute of Hypertension Shanghai Key Laboratory of Hypertension Ruijin Hospital Shanghai Jiaotong University School of Medicine Shanghai ChinaUniversity of the East Ramon Magsaysay Memorial Medical Center IncDivision of Hypertension Department of Medicine Faculty of Medicine Siriraj Hospital Mahidol University Bangkok ThailandDepartment of Internal Medicine University of Medicine and Pharmacy Hue University Hue City VietnamDepartment of Physiology King George's Medical University Lucknow IndiaDivision of Cardiovascular Medicine Department of Medicine Jichi Medical University School of Medicine Tochigi JapanFaculty of Cardiology Service Hanyang University Medical Center Seoul KoreaSchool of Medicine and Health Sciences Atma Jaya Catholic University of Indonesia Jakarta IndonesiaDepartment of General Medicine Tan Tock Seng Hospital Singapore City SingaporeDivision of Nephrology Department of Medicine Yong Loo Lin School of Medicine Singapore SingaporePunjab Medical Center Lahore PakistanSection of Cardiology Department of Medicine Medical Center Manila Manila PhilippinesDepartment of Cardiology Fu Wai Hospital Chinese Academy of Medical Sciences & Peking Union Medical College Beijing ChinaDepartment of Internal Medicine National Taiwan University College of Medicine Taipei City TaiwanDepartment of Medicine National Yang‐Ming University School of Medicine Taipei Taiwan;

展开▼
收录信息
原文格式 PDF
正文语种英语
中图分类
关键词
Asian population; cardiovascular disease; polypill; primary prevention;

The feasibility of polypill for cardiovascular disease prevention in Asian Population

摘要

著录项

相关主题

期刊订阅